Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.

Slides:



Advertisements
Similar presentations
Dott. Carlo Garufi Oncologia Medica C Istituto Regina Elena, Roma Scuola Mediterranea di Oncologia “Actigrafia nel tumore della mammella” Roma
Advertisements

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev
Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉 財團法人台灣癌症臨床研究發展基金會.
Metastatic Gastric Cancer
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.
CM A pooled safety & efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials of 6,286 patients.
1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.
IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)
Impact of the Type and Modalities of Preoperative Chemotherapy on the Outcome of Liver Resection for Colorectal Metastases R. Adam, E. Barroso, C. Laurent,
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
PREOPERATIVE PLASMA CONCENTRATION OF MMP-9/TIMP-1 COMPLEXES IS NOT ASSOCIATED WITH DISEASE OUTCOME IN PRIMARY BREAST CANCER (N=483) Anne-Sofie Schrohl.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.
Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.
Supplemental Figures Loss of circadian clock gene expression is associated with tumor progression in breast cancer Cristina Cadenas 1*, Leonie van de Sandt.
What would you recommend as first line therapy for a 68 y/o woman with advanced pancreatic cancer and limited metastatic disease with ECOG-1? Gemcitabine.
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
Selection of Patient Samples and Genes for Disease Prognosis Limsoon Wong Institute for Infocomm Research Joint work with Jinyan Li & Huiqing Liu.
Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,
*University Hospital Gasthuisberg, Leuven, Belgium
Predicting toxicity for patients with advanced Gastrointestinal Stromal Tumors (GIST) treated with imatinib mesylate : an EORTC/ISG/AGITG randomized trial.
Introduction Results Material and Methods Conclusions Genetic variants predict clinical outcome clinical outcome in patients (pts) with metastatic colorectal.
This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.
Cancer Stem Cell SNPs Have Opposite Prognostic Outcome in Patients with Gastric Cancer Among Asian and Western Countries Melissa J. LaBonte 1, Takeru Wakatsuki.
O’Shaughnessy J et al. Proc ASCO 2011;Abstract 1007.
Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)
Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.
T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.
Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.
EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.
Risk Stratified Analysis Improves Prediction of Treatment Benefit Over Subgroup Analysis: Findings from Intergroup N9741 HK Sanoff, ME Campbell, HC Pitot,
Mace L. Rothenberg, M.D. Professor of Medicine Ingram Professor of Cancer Research Biomarkers in Colorectal Cancer Management: KRAS Mutations and EGFR.
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.
0 Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer NCCTG Intergroup Phase III Trial N0147 Jocelin Huang, Daniel J Sargent,
KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.
Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.
Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.
Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.
Pan-cancer analysis of prognostic genes Jordan Anaya Omnes Res, In this study I have used publicly available clinical and.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.
Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
Reviewer: Dr Scott Berry Date posted: June 21, 2007 CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized.
Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC experience.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
Pharmacogenetics of Irinotecan Clinical perspectives: utility of genotyping Mark J. Ratain, MD University of Chicago 11/3/04.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer In association.
Higher Vitamin D Levels Associated With Improved Survival in Metastatic Colorectal Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
CCO Independent Conference Coverage
Immunoscore Prognostic in Colon Cancer
Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer CCO Independent Conference Highlights* of the.
Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors of Survival J Tabernero,
MCW Regional Cancer Therapy Program
BRAF mutant mCRC patients – What would you recommend? FOLFIRINOX/Bev
Ospedale Misericordia, Grosseto
UHRF1 is regulated by miR-9 in colorectal cancer
miRNA expression patterns in stools from healthy subjects.
First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.
Progression-Free Survival Times Overall Survival Times
Published online September 20, 2017 by JAMA Surgery
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
Fluorouracil, Oxaliplatin, CPT-11: Use and Sequencing (MRC FOCUS)
Uni- & Multivariate Analysis Sponsored by GERCOR (
Presentation transcript:

Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic colorectal cancer (mCRC) S. IACOBELLI, P. Innominato, M. Piantelli, G. Bjarnason, B. Coudert, C. Focan, S. Giacchetti, A. Poncet, C. Garufi, F. Levi, and the ARTBC Chronotherapy Group

Authors’ disclosure The Authors indicate no potential conflicts of interest

Learning Objectives: Role of the Circadian Timing System in malignant processes Evaluate the correlations between the expression of clock proteins in healthy colonic mucosa and primary colon cancer Assess the prognostic value of the molecular clock in human cancer

The Molecular Clock Levi F, Schibler U. Annu Rev Pharmacol Toxicol 2007;47: Harmer SL, Panda S, Kay SA. Annu Rev Cell Dev Biol 2001;17:215-53

Circadian control of drug metabolism; Tight link between molecular clock components and cell cycle, DNA repair and apoptosis Mutant clock genes and cancer risk PER1 & PER2 functioning as oncosuppressors Role of the molecular clock in malignant processes Levi F, Schibler U. Annu Rev Pharmacol Toxicol 2007;47: Hunt T, Sassone-Corsi P. Cell 2007 May 4;129(3):461-4 Zhu Y, Leaderer D, Guss C, et al. Int J Cancer 2007 Jan 15;120(2):432-5 Zhu Y, Brown HN, Zhang Y, et al. Cancer Epidemiol Biomarkers Prev 2005 Jan;14(1): Fu L, Pelicano H, Liu J, Huang P, et al. Cell 2002 Oct 4;111(1): Gery S, Komatsu N, Baldjyan L, et al. Mol Cell 2006 May 5;22(3):375-82

OBJECTIVE To assess whether the expression patterns of PER1, PER2 and PER3 proteins in primary tumor or healthy mucosa predicts for clinical outcome in chemo-naive patients with mCRC receiving a combination of oxaliplatin, 5-fluorouracil and folinic acid in a randomized phase III trial (EORTC trial 05963) of flat vs. chronomodulated infusion

METHODS PER1, PER2 and PER3 expression evaluated by immunohistochemistry; Healthy mucosa samples: categorized according to the % of positive cells –Negative: ≤ 5% –Weakly positive: >5%- ≤ 20% –Strongly positive: > 20% Primary tumors: % of labelled cells categorized according to terciles.

The correlations between the expression patterns of each PER between healthy mucosa and primary tumor were computed Univariate and multivariate analyses were performed from time of inclusion in the study till the event using the aforementioned categories. STATISTICAL ANALYSIS

Paraffin wax embedded samples of primary tumor were collected for 198 patients. In 169 of them, healthy mucosa was also present. RESULTS – sample size

RESULTS –patients’ characteristics CharacteristicNo% Age (yrs) median range Sex Male Female Treatment Conv Chrono WHO PS CharacteristicNo% No Mets sites CEA normal abnormal

RESULTS – PERs expression in mucosa Negative Weak Strong PER1 PER2 PER3

RESULTS – PER2 in Mucosa Negative Weak Strong

RESULTS – PER2 in Tumor 0% 100%

The expression pattern of any PER protein is not influenced by gender, age, site of primary tumor and no. of metastatic sites. RESULTS – clinical features

The expression pattern of any PER protein in healthy mucosa was not associated with statistically significant differences in OS. No association was found between the % of labelled tumor cells for PER1 or PER3 and OS. RESULTS – overall survival

RESULTS – PER2 & overall survival The greater the % of stained tumor cells for PER2, the longer the survival at univariate analysis (Log-rank, p=0.04; Log-rank for trend, p= 0.013) Median (months) 2 yrs (%)5 yrs (%) 1 st tercile nd tercile rd tercile

No. At risk 1° tercile ° tercile ° tercile Log-rank, p = Log-rank for trend p= RESULTS – PER2 & overall survival

A multivariate Cox model was computed using PER2%+Tum terciles, WHO-PS, # of metastatic sites, presence of metastases at diagnosis, age, gender and treatment arm as covariates. RESULTS – multivariate analysis

The independent prognostic value of PER2%+Tum terciles was confirmed, together with PS and # of metastatic sites involved. HR (95% CI)p value PER2 terciles 1 st vs 2 nd 1 st vs 3 rd 0.74 ( ) 0.58 ( ) WHO PS 0 vs 1 0 vs ( ) 3.7 ( ) No. Mets sites 1 vs 2 1 vs ≥3 1.5 ( ) 2.2 ( )

Summary PER3 clock protein expression in healthy mucosa and primary tumor were correlated. Lower expression of PER2 in tumor cells was associated with a shorter survival.

Conclusions Down-regulation of core clock gene Per2 in tumors predicted for poor survival in chemo-naive pts with metastatic colorectal cancer. This is the first report of an association between clock gene down regulation and outcome in metastatic colorectal cancer.

RESULTS – PERs expression in tumor PER1 PER2 PER3 1 st tercile 2 nd tercile 3 rd tercile

RESULTS - correlations A positive correlation between the expression pattern of PER3 in healthy mucosa and primary tumor was found (p=0.002, Pearson’s  2 ). Mucosa 1 st tercile2 nd tercile3 rd tercile Negative Weak Strong PER3